NCT02731131View on ClinicalTrials.gov

A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Hepatitis D, Chronic
Interventions
DRUG

Peginterferon alfa-2a

Peginterferon alfa-2a will be administered as 180 micrograms (mcg) once weekly via subcutaneous (SC) injection.

DRUG

Ribavirin

Ribavirin will be administered as 1000 to 1200 milligrams (mg) per day in divided oral doses.

Trial Locations (1)

09042

Cagliari

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02731131 - A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD) | Biotech Hunter | Biotech Hunter